TrialBMC cancer2019

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

Maria Di Bartolomeo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.